Group 1 - The core focus of the event is the announcement of the "Annual Innovation Award" winners, recognizing companies with significant breakthroughs and innovations in the capital market [1] - The awarded companies include Guangfeng Technology, Corning Jereh Pharmaceutical-B, KEEP, Mindray Medical, Ruihe Zhizhi, AAC Technologies, 37 Interactive Entertainment, Tongwei Co., Xinghuan Technology-U, and Ginkgo Bioworks, with no specific ranking [1] - The "Annual Innovation Award" aims to highlight companies that excel in innovation across various dimensions, including technology research and development, products, and business models [1] Group 2 - The "Golden Award" evaluation is designed to create a reference list of the most valuable listed companies and unicorns in the investment community, covering all listed companies on major exchanges [2] - The evaluation includes companies listed on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [2]

Core Insights - The "Annual Innovation Award" recognizes companies with breakthrough and innovative capabilities in the capital market, emphasizing the importance of innovation in technology research and development, products, and business models [1][2] - The award selection process involved quantitative data analysis and expert review to determine the final results [1] Group 1: Award Winners - Ten companies were awarded the "Annual Innovation Award," including Guangfeng Technology, Corning Jereh Pharmaceutical-B, KEEP, Mindray Medical, Ruihe Smart, AAC Technologies, 37 Interactive Entertainment, Tongwei Co., Xinghuan Technology-U, and Ginkgo Bioworks [1] - The award aims to highlight companies that are committed to exploring cutting-edge technology and paving new paths for development, thereby leading the industry and promoting social progress [1] Group 2: Evaluation Scope - The "Golden Award" evaluation covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2]

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced its first pullback after three consecutive gains, with the popular Hong Kong Stock Connect innovative drug ETF (520880) dropping nearly 1% in the afternoon, indicating active buying interest despite the decline [1] - Major innovative drug stocks saw more declines than gains, with Kangfang Biopharma and China National Pharmaceutical Group both falling over 2%, while several others, including Yundingshinyao and Nuocheng Jianhua, dropped over 3% [1] - The recent policy initiatives from various cities, including Xi'an's plan to enhance the biopharmaceutical industry, aim to support the development of innovative drugs, particularly in areas like stem cell and peptide drugs [1] Group 2 - Changjiang Securities noted that the pharmaceutical industry is experiencing a policy cyclical phase, with supportive policies for the innovative drug sector gradually being implemented, indicating a new development cycle for innovative drugs [3] - Investors are encouraged to focus on high-quality innovative drug assets, particularly those with strong overseas potential, and to consider the Hong Kong Stock Connect innovative drug ETF (520880) as a low-entry point opportunity [3] - The index tracked by the Hong Kong Stock Connect innovative drug ETF has unique advantages, including a pure focus on innovative drug companies, a significant weight of over 72% in leading companies, and better risk control through reduced weight on less liquid stocks [3][4] Group 3 - The top ten holdings in the Hong Kong Stock Connect innovative drug ETF account for 72.57% of the total weight, showcasing the dominance of leading companies in the sector [4] - The ETF is positioned as a high-potential investment option for those looking to reduce volatility while still focusing on innovative drugs, with a significant portion of its holdings in traditional Chinese medicine to mitigate risks [4][5] - The Hong Kong Stock Connect innovative drug ETF has a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception, making it the largest and most liquid ETF tracking the same index [5]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector experienced its first pullback after three consecutive gains, with the popular Hong Kong Stock Connect innovative drug ETF (520880) seeing a decline of nearly 1% in the afternoon, indicating active buying interest despite the drop [1]. Group 1: Market Performance - The leading innovative drug stocks mostly declined, with Kangfang Biopharma and China National Pharmaceutical Group both dropping over 2%, while several other stocks like Yunding Xinyao, Nuocheng Jianhua, and Ascentage Pharma-B fell more than 3% [1]. Group 2: Policy Developments - Xi'an recently released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)," aiming to break through key core technologies in drug development across various fields, including stem cell drugs and peptide drugs [3]. - Multiple regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies this year to promote high-quality development in the innovative drug sector [3]. Group 3: Investment Insights - Changjiang Securities noted that the pharmaceutical industry is experiencing a certain policy cyclicality, with supportive policies for the innovative drug industry gradually being implemented, such as the introduction of insurance incremental funds and expedited clinical trial approvals [3]. - Investors are encouraged to focus on high-quality innovative drug assets, particularly those with "hard innovation" and strong overseas potential [3]. - The Hong Kong Stock Connect innovative drug ETF (520880) is highlighted as a top choice, with its underlying index, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, offering three unique advantages: purity, significant weight of leading companies, and better risk control [3][4][5]. Group 4: ETF Characteristics - The top ten innovative drug leaders account for over 72% of the ETF's weight, showcasing the strength of leading companies in the sector [4]. - The ETF has a total market capitalization of approximately HKD 12.87 billion, with the top ten holdings including companies like BeiGene (11.51% weight) and Innovent Biologics (10.19% weight) [6]. - For those looking to invest in innovative drugs while minimizing volatility, the only drug ETF in the market (562050) is recommended, which focuses on the top 50 A-share pharmaceutical companies, with about 60% in innovative drugs and 25% in traditional Chinese medicine [7].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector experienced its first pullback after three consecutive gains, with the popular Hong Kong Stock Connect innovative drug ETF (520880) dropping nearly 1% in the afternoon, indicating active buying interest despite the decline [1][8]. Group 1: Market Performance - The innovative drug sector saw a majority of leading stocks decline, with Kangfang Biopharma and China National Pharmaceutical Group both dropping over 2%, while several others, including Yunding Xinyao and Nuocheng Jianhua, fell more than 3% [1][8]. - The Hong Kong Stock Connect innovative drug ETF (520880) has a significant concentration in leading stocks, with the top ten holdings accounting for over 72% of the index [4][12]. Group 2: Policy and Industry Support - Xi'an recently released a plan to enhance the biopharmaceutical industry's capabilities from 2025 to 2027, focusing on breakthroughs in key drug development technologies in areas such as stem cell drugs and peptide drugs [3][10]. - Various regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to promote high-quality development in the innovative drug sector this year [3][10]. - Changjiang Securities noted that the pharmaceutical industry is experiencing a policy cycle, with comprehensive support policies for the innovative drug sector gradually being implemented [9]. Group 3: Investment Opportunities - Investors are encouraged to consider the Hong Kong Stock Connect innovative drug ETF (520880) and its associated funds as a low-entry point opportunity, particularly focusing on "hard innovation" assets and those with strong overseas potential [9][11]. - The index tracked by the ETF, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, offers three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and employs measures to control risks associated with less liquid stocks [11][12]. - For those looking to mitigate volatility while investing in innovative drugs, the only drug ETF in the market (562050) and its associated funds are recommended, which also include a significant allocation to traditional Chinese medicine [12][13].

Group 1: Market Overview - The pharmaceutical and biotechnology index decreased by 0.14% from December 15 to December 19, outperforming the ChiNext and CSI 300 indices [1][23] - The total trading volume in the pharmaceutical sector was 389.82 billion yuan, accounting for 4.49% of the total trading volume in the Shanghai and Shenzhen markets, which is below the average of 7.12% since 2013 [1][38] - The pharmaceutical sector ranked 18th in terms of weekly performance among all industries during the same period [1][25] Group 2: Sector Analysis - The recent lack of significant industrial catalysts has led to a muted beta effect in the sector, but many stocks have entered a value range, indicating potential for a rebound [2][59] - The "reward economy" theme has positively influenced certain pharmaceutical companies, particularly those linked to Ant Group and related retail channels [2][59] - Strong performance was noted in CXO, small nucleic acids, and certain innovative drugs, driven by specific stock factors such as BD expectations and overseas mapping [2][59] Group 3: In Vivo CAR-T Developments - In vivo CAR-T technology is expected to address the accessibility issues of CAR-T therapies, potentially lowering treatment costs and making it available as a shelf product [4][12] - Major pharmaceutical companies are actively investing in in vivo CAR-T, with business development (BD) transactions exceeding 5 billion USD, indicating its strategic importance [4][16] - Clinical data presented at the 2025 ASH meeting showed promising results for in vivo CAR-T therapies, with high rates of minimal residual disease (MRD) negativity in patients [4][19] Group 4: Future Outlook - The company maintains a positive outlook on innovation, international expansion, and turnaround opportunities in the pharmaceutical sector, focusing on BD 2.0, small nucleic acids, and supply chains as key investment areas [3][22] - The upcoming 2026 potential catalysts include the publication of the commercial insurance innovation drug directory and the commercialization of targeted CAR-T therapies [21][22] - Domestic companies are rapidly advancing in the in vivo CAR-T space, with several candidates in early clinical stages, indicating a growing competitive landscape [22][22]

Investment Rating - The report maintains an investment rating of "Outperform" with a target of A [7] Core Insights - The report highlights the positive results from Takeda's new generation oral TYK2 inhibitor, zasocitinib (TAK-279), for treating moderate to severe plaque psoriasis, with over 50% of participants achieving skin clearance or nearly clear skin (PASI 90) at week 16, and about 30% achieving complete clearance (PASI 100) [3][4] - The report suggests that there are multiple catalysts expected in the sector, including academic conferences and data readouts, which could provide investment opportunities [2] - The report emphasizes the potential of other TYK2 inhibitors, particularly Eifang Biopharma's D-2570, which has shown promising phase 2 clinical data [4][22] Summary by Sections Weekly New Drug Market Review - From December 15 to December 21, 2025, the top five gainers in the new drug sector were: Yahu Medicine (+12.03%), Cloudtop New Medicine (+9.32%), Aidi Pharmaceutical (+9.06%), Shiyao Group (+7.05%), and Ailis (+3.94%). The top five losers were: Chuangsheng Group (-16.03%), Beihai Kangcheng (-12.33%), Kedi (-11.88%), WuXi AppTec (-11.15%), and Nuocheng Jianhua (-10.99%) [1][17] Weekly Focus on Recommended Stocks - The report recommends focusing on companies with high certainty for overseas expansion, such as Sanofi Biopharma, Lianbang Pharmaceutical, and Kelun Biotech. It also highlights companies with potential overseas data catalysts, including Betta Pharmaceuticals, Hutchison China MediTech, and Ying'en Biopharma [2][21] Weekly New Drug Industry Analysis - Takeda's phase 3 clinical trials for zasocitinib have shown consistent results with previous phase 2 trials, indicating strong data reliability. The report also notes the potential for TYK2 inhibitors in treating Crohn's disease and ulcerative colitis [3][4][22] Weekly New Drug Application Approval & Acceptance - No new drug or new indication applications were approved domestically this week, but 11 new drug or new indication applications were accepted [5][26] Weekly New Drug Clinical Application Approval & Acceptance - This week, 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [11][28]

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The overall market is experiencing a pullback driven by technology giants, with the Hang Seng Index down by 1.1% and the Hang Seng Composite Index down by 1.2% [1] - Valuation levels for most industries are declining, with the Hang Seng Index's forward P/E ratio decreasing by 1.7% to 11.6x [2] - Earnings expectations have been adjusted upwards overall, with the Hang Seng Index's EPS increasing by 0.3% compared to the previous week [3] Summary by Sections Market Performance - The Hang Seng Index decreased by 1.1%, while the Hang Seng Composite Index fell by 1.2%. Mid-cap stocks outperformed small-cap and large-cap stocks [1] - Among major concept indices, the Hang Seng Consumer Index rose by 0.3%, while the Hang Seng Internet Index dropped by 2.9% [1] Valuation Levels - The valuation of the Hang Seng Index decreased by 1.7% to 11.6x, and the Hang Seng Composite Index's valuation fell by 2.4% to 11.4x [2] - The most significant valuation increase was in the basic chemicals sector (+11.6%), while the real estate sector saw the largest decline (-19.0%) [2] Earnings Expectations - The EPS for the Hang Seng Index increased by 0.3%, and the Hang Seng Composite Index's EPS rose by 1.2% compared to the previous week [3] - The real estate sector saw a substantial EPS upward revision of 20.5%, while the basic chemicals sector experienced a downward revision of 10.2% [3]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights a concentrated trend of domestic innovative drug collaborations and transactions as the year ends, with expectations for value recovery in 2026 [1][4] - The overall market performance shows a decline, with the Hang Seng Index down 0.8% and the Hang Seng Healthcare Index down 4.3% during the week [4][7] - The report emphasizes the importance of stock selection logic returning to fundamentals and valuations, focusing on stocks that are currently undervalued with expected fundamental improvements [4] Valuation Summary - The report provides a detailed valuation overview of various companies, indicating target prices and earnings per share estimates for FY25E and FY26E, along with their respective price-to-earnings ratios [3] - Notable companies with "Buy" ratings include AstraZeneca, BeiGene, and Hansoh Pharmaceutical, with target prices significantly above current trading prices [3] Market Trends - The report notes a slight decrease in domestic institutional holdings through the Hong Kong Stock Connect, while foreign holdings remain stable [33] - The report identifies a trend of increasing positions in leading innovative pharmaceutical companies by domestic investors, particularly in companies like Heng Rui Medicine and Rongchang Bio [36] Investment Insights - The report mentions several significant business development (BD) transactions exceeding $1 billion, indicating a robust pipeline for innovative drugs [4][5] - It recommends focusing on specific segments such as innovative drugs and CXO companies that are expected to benefit from downstream recovery and high market demand [4]

Core Insights - The article highlights the recognition of CloudTop New Health for its innovative strategies and achievements in the biopharmaceutical industry, winning multiple awards for its performance in drug development and commercialization [1][3]. Group 1: Awards and Recognition - CloudTop New Health received the "Annual Outstanding Innovative Pharmaceutical Newcomer" and "Annual Outstanding Drug Research and Development Innovation Enterprise" awards at the 2025 21st Century Health Industry Competitiveness Research [1]. - The company was also listed among the "Top 40 Leading Enterprises in China's Innovative Drug Export" at the 2025 Singapore Business and Charity Forum, showcasing its strengths in independent research and international clinical advancement [1]. Group 2: Product Performance - The product Renfukang® achieved sales revenue of 303 million yuan in the first half of 2025, marking an 81% year-on-year increase, with total sales expected to reach 1.2 to 1.4 billion yuan for the full year [3]. - The antibiotic product Yijia® generated sales of 143 million yuan in the first half of 2025, reflecting a 6% increase, with a significant 37% growth in sales to core hospitals [4]. Group 3: Strategic Developments - CloudTop New Health's 2030 strategy emphasizes a "BD cooperation + self-research" dual-driven approach to enhance its global presence and innovation capabilities [7]. - The company plans to expand its product pipeline to over 20 commercialized products by 2030, including Renfukang®, Weishiping®, Yijia®, and others, targeting a revenue scale exceeding 15 billion yuan [9]. Group 4: Future Outlook - The company anticipates a compound annual growth rate of over 50% from 2025 to 2030, with a goal to maintain growth rates above 15% post-2030 [9]. - CloudTop New Health aims to maximize commercial value through diverse methods, including independent research and licensing, while accelerating the global rollout of its innovative drugs [9].